69 related articles for article (PubMed ID: 30486324)
1. Financial burden in a US cohort of patients with HCC.
Desai R; Jiang Y; VanWagner LB; Singal AG; Lieber SR
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38829203
[TBL] [Abstract][Full Text] [Related]
2. Productivity loss by cancer stage in patients newly diagnosed with hepatocellular carcinoma: A claims database analysis.
Cheng SJ; Bansal A; Veenstra DL
J Manag Care Spec Pharm; 2024 Jun; 30(6):572-580. PubMed ID: 38824631
[TBL] [Abstract][Full Text] [Related]
3. Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada.
Seung SJ; Saherawala H; Zagorski B; Tong C; Lim H; Kim P; Marquez V; Gill S; Liu D; Davies JM
Hepat Oncol; 2023 Dec; 10(4):HEP50. PubMed ID: 38495452
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of Hepatocellular Carcinoma in Taiwan.
Lai YW; Chung CH
Clin Pract; 2024 Mar; 14(2):570-578. PubMed ID: 38666802
[TBL] [Abstract][Full Text] [Related]
5. No Association between Depression and Risk of Hepatocellular Carcinoma in Older People in Taiwan.
Lai SW; Lin CL; Liao KF; Chen WC
ISRN Psychiatry; 2013; 2013():901987. PubMed ID: 24392241
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.
Chang PY; Huang CC; Hung CH; Yu CY; Wu DK; Hwang JI; Liang PC; Wu RH; Tsai WL; Lin YJ; Liu YS; Liang HL; Lee RC; Chen CH
Liver Cancer; 2018 Oct; 7(4):312-322. PubMed ID: 30488021
[TBL] [Abstract][Full Text] [Related]
7. Disease Burden of Hepatocellular Carcinoma: A Global Perspective.
Sayiner M; Golabi P; Younossi ZM
Dig Dis Sci; 2019 Apr; 64(4):910-917. PubMed ID: 30835028
[TBL] [Abstract][Full Text] [Related]
8. A hierarchical multilabel graph attention network method to predict the deterioration paths of chronic hepatitis B patients.
Wu ZE; Xu D; Hu PJ; Huang TS
J Am Med Inform Assoc; 2023 Apr; 30(5):846-858. PubMed ID: 36794643
[TBL] [Abstract][Full Text] [Related]
9. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Khanam A; Kottilil S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613878
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review.
Zou H; Li M; Lei Q; Luo Z; Xue Y; Yao D; Lai Y; Ung COL; Hu H
Front Public Health; 2022; 10():801981. PubMed ID: 35530735
[TBL] [Abstract][Full Text] [Related]
11. Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China.
Wu J; Liu C; Wang F
Front Public Health; 2021; 9():742355. PubMed ID: 34805067
[No Abstract] [Full Text] [Related]
12. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study.
Chu SS; Kuo YH; Liu WS; Wang SC; Ho CH; Chen YC; Yang CC; Wu HC
Sci Rep; 2021 Jan; 11(1):1614. PubMed ID: 33452421
[TBL] [Abstract][Full Text] [Related]
13. A cost of illness analysis of hepatocellular carcinoma for the Greek healthcare setting.
Athanasakis K; Pliarchopoulou F; Naoum V; Psarrakis C; Tziolos N; Marantos T; Damoulari C; Chounta A
Gastroenterol Hepatol Bed Bench; 2020; 13(3):219-222. PubMed ID: 32821351
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis.
Xu M; Zhou Z; Xu R; Zhang H; Lin N; Zhong Y
World J Surg Oncol; 2019 Mar; 17(1):45. PubMed ID: 30823932
[TBL] [Abstract][Full Text] [Related]
15. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan.
Nguang SH; Wu CK; Liang CM; Tai WC; Yang SC; Ku MK; Yuan LT; Wang JW; Tseng KL; Hung TH; Hsu PI; Wu DC; Chuah SK; Hsu CN
Int J Environ Res Public Health; 2018 Nov; 15(12):. PubMed ID: 30486324
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.
Qian MY; Yuwei J R; Angus P; Schelleman T; Johnson L; Gow P
J Gastroenterol Hepatol; 2010 May; 25(5):951-6. PubMed ID: 20546449
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
[TBL] [Abstract][Full Text] [Related]
18. Calculation of operating expenses for conventional transarterial chemoembolization in an academic medical center: a step toward defining the value of transarterial chemoembolization.
Beheshti MV; Meek J
J Vasc Interv Radiol; 2014 Apr; 25(4):567-74. PubMed ID: 24462006
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN
J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
